Hal Bar­ron gam­bles $625M cash on high-wire TIG­IT act, throw­ing Glax­o­SmithK­line in­to heat­ed race and com­plet­ing next-gen I/O trin­i­ty

Count Hal Bar­ron and Glax­o­SmithK­line in for the TIG­IT fight.

The stakes are as high as the risks: While a grow­ing pack of Big Phar­ma ri­vals is lend­ing cre­dence to the hy­poth­e­sis that TIG­IT will be the next big im­mune check­point and can­cer drug tar­get, the first clin­i­cal tri­als have shown re­sponse rates that can be de­scribed as mod­est at best. But Bar­ron’s bet is on the whole “ax­is” that the re­cep­tor sits on, with an eye on test­ing its new an­ti-TIG­IT an­ti­body not just in com­bo with PD-1 but al­so in triplets.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER